JINGXIN has repurchased 5.49% of its shares, costing 609 million yuanZhitong·Sep 3, 2025 at 10:05 AM002020-2.03%
JINGXIN: Net profit in the first half of 2025 is 388 million yuan, a year-on-year decrease of 3.54%Zhitong·Aug 26, 2025 at 11:57 AM002020-2.03%
JINGXIN: As of the announcement date, a total of 290 million yuan of the raised funds for temporarily supplementing working capital has been fully returned to the special account for raised funds, and the usage period has not exceeded 12 monthsZhitong·Aug 15, 2025 at 03:59 AM002020-2.03%
The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also risingZhitong·Aug 12, 2025 at 01:36 AM600572-0.48%300026-2.25%
JINGXIN: Currently, it has not yet involved in the field of brain-machine interface technologyZhitong·Aug 8, 2025 at 09:11 AM002020-2.03%
Innovative drug concept rebounds after hitting the bottom, Junshi Biosciences and others rise over 5%Zhitong·Aug 8, 2025 at 02:29 AM002020-2.03%300436-3.35%
JINGXIN Pharmaceutical signed a patent licensing agreement related to the hydrochloride of carbidopa formulations and raw materialsZhitong·Aug 7, 2025 at 10:23 AM002020-2.03%
Innovative drug concept stocks saw a partial rebound, with Hanyu Pharmaceutical surging over 10% in the afternoon, Hicin Pharmaceutical, Sun-Novo, and Guangshengtang also rising over 10%. Fuyuan Pharmaceutical and WEDGE CORPORATION hit the daily limit, while Longshen Rongfa, JINGXIN, CSBIO, and Staidson BioPharm followed suitZhitong·Aug 4, 2025 at 05:09 AM300584-4.28%688621-1.17%
JINGXIN: The proportion of shares repurchased by the company has reached 5%Zhitong·May 7, 2025 at 10:04 AM002020-2.03%
JINGXIN released its first-quarter performance, with a net profit attributable to the parent company of 163 million yuan, a year-on-year decrease of 4.62%Zhitong·Apr 27, 2025 at 09:24 AM002020-2.03%
JINGXIN released its 2024 annual performance, with a net profit attributable to the parent company of 712 million yuan, an increase of 15.04%Zhitong·Apr 2, 2025 at 11:11 AM002020-2.03%
JINGXIN has repurchased 4.08% of its shares, costing 443 million yuanZhitong·Mar 31, 2025 at 09:19 AM002020-2.03%
JINGXIN's cumulative repurchase ratio reached 4%, costing 434 million yuanZhitong·Mar 21, 2025 at 09:27 AM002020-2.03%
JINGXIN: Adjusted the repurchase fund limit to 700 million yuanZhitong·Mar 7, 2025 at 09:36 AM002020-2.03%
